|
Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL). |
|
|
Stock and Other Ownership Interests - Altor BioScience; Celldex; CytomX Therapeutics |
Honoraria - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche |
Consulting or Advisory Role - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche |
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst) |
Patents, Royalties, Other Intellectual Property - named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lion Biotechnologies; Merck; Merck; Novartis; Pieris Pharmaceuticals; Roche |
|
|
Research Funding - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck Sharp & Dohme; Pfizer; Roche |
|
|
Honoraria - Agenus; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Grunenthal; Immunocore; Incyte; LEO Pharma; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sysmex |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Grunenthal; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech; Sysmex |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech |
|
|
Stock and Other Ownership Interests - Potenza Therapeutics; Vesuvius Pharmaceuticals |
|
Consulting or Advisory Role - Advaxis; Amgen; AstraZeneca; Beigene; Bristol-Myers Squibb; Chugai Pharma; FSC Pediatrics; Genentech; Jounce Therapeutics; Lilly; MedImmune; Merck; Polaris; Polynoma; Potenza Therapeutics; Sellas Life Sciences; Tizona Therapeutics, Inc.; ZIOPHARM Oncology |
Research Funding - Bristol-Myers Squibb (Inst) |
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus.; I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals. |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Chugai Pharma; Janssen; Kadmon; Regeneron; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda |
Research Funding - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; Merck; Novartis; Roche |
Expert Testimony - EMD Serono |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Novartis |
|
|
Honoraria - Amgen; GlaxoSmithKline |
Consulting or Advisory Role - Genentech; GlaxoSmithKline |
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Novartis |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Genentech/Roche; Immunocore; Merck |
Speakers' Bureau - Genentech/Roche; Janssen Oncology |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Janssen; Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Antares Pharmaceuticals (I) |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Castle Biosciences; Genentech; Novartis |
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Celldex (Inst); Checkmate Pharmaceuticals (Inst); Dynavax Technologies (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Reata Pharmaceuticals (Inst); Syndax (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Castle Biosciences; Genentech; Novartis |